Engineered antibodies to combat viral threats

Yu, Xiaojie; Cragg, Mark S.

doi:10.1038/d41586-020-03196-2

NEWS AND VIEWS
18 November 2020

Engineered antibodies to combat viral threats

As the COVID-19 pandemic rages globally, interest in antiviral treatments has never been higher. Antibodies are key defence components, and engineering them to better exploit their natural functions might boost therapeutic options.

Xiaojie Yu ⁰ &
Mark S. Cragg ¹

Xiaojie Yu
1. Xiaojie Yu is in the Centre for Cancer Immunology, School of Cancer Sciences, University of Southampton Faculty of Medicine, Southampton SO16 6YD, UK.
View author publications

You can also search for this author in PubMed Google Scholar
Mark S. Cragg
1. Mark S. Cragg is in the Centre for Cancer Immunology, School of Cancer Sciences, University of Southampton Faculty of Medicine, Southampton SO16 6YD, UK, and at the Institute for Life Sciences, University of Southampton.
View author publications

You can also search for this author in PubMed Google Scholar

Access through your institution

Buy or subscribe

The use of antibodies to combat human disease dates back to the 1890s. At that time, the physiologist Emil von Behring used blood extracts from rabbits infected with the bacterium that causes diphtheria to tackle that infection. It was discovered only later that antibodies targeting the bacterium were the active ingredient. Amazingly, such serum therapy is still practised today. For example, blood (described as convalescent plasma) donated by people who have recovered from COVID-19, which contains antibodies targeting the SARS-CoV-2 virus, is used as a treatment for people with coronavirus infection. Writing in Nature, Bournazos et al.¹ report progress in efforts to aid antiviral responses by engineering human antibodies to enhance their antiviral activity.

Access options

Access through your institution

Buy article

Get time limited or full article access on ReadCube.

$32.00

Buy

All prices are NET prices.

Nature 588, 398-399 (2020)

doi: https://doi.org/10.1038/d41586-020-03196-2

References

Bournazos, S., Corti, D., Virgin, H. W. & Ravetch, J. V. Nature 588, 485–490 (2020).
Article Google Scholar
Nimmerjahn, F. & Ravetch, J. V. Nature Rev. Immunol. 8, 34–47 (2008).
PubMed Article Google Scholar
Urquhart, L. Nature Rev. Drug Discov. 19, 228 (2020).
PubMed Article Google Scholar
Liu, R., Oldham, R. J., Teal, E., Beers, S. A. & Cragg, M. S. Antibodies 9, 64 (2020).
Article Google Scholar
Shields, R. L. et al. J. Biol. Chem. 276, 6591–6604 (2001).
PubMed Article Google Scholar
Beers, S. A., Glennie, M. J. & White, A. L. Blood 127, 1097–1101 (2016).
PubMed Article Google Scholar
Chan, K. R., Ong, E. Z., Mok, D. Z. & Ooi, E. E. Expert Rev. Anti-Infect. Ther. 13, 1351–1360 (2015).
PubMed Article Google Scholar
Minard-Colin, V. et al. Blood 112, 1205–1213 (2008).
PubMed Article Google Scholar
Goncalvez, A. P., Engle, R. E., St. Claire, M., Purcell, R. H. & Lai, C.-J. Proc. Natl Acad. Sci. USA 104, 9422–9427 (2007).
PubMed Article Google Scholar
Kerntke, C., Nimmerjahn, F. & Biburger, M. Front. Immunol. 11, 118 (2020).
PubMed Article Google Scholar

Download references

Competing Interests

M.S.C. acts as a consultant for a number of biotech companies, being retained as a consultant for BioInvent, and has received research funding from BioInvent, GSK, UCB, iTeos and Roche. None of these associations relate to antiviral therapy.